Part D results
CMS's year-end Part D reconciliation, 2022–2024. When a plan's actual drug costs land well above its bid, CMS shares the loss through risk sharing (the "risk corridors"); when they land well below, the plan pays CMS back. A large positive amount means the plan's drug bid was badly underpriced. 2024 is the latest year CMS has published.
How to read this
Risk sharing: positive = CMS paid the plan (costs ran over the bid by more than the corridor); negative = the plan paid CMS. These are CMS's settled figures. Plans also report risk sharing in their MLR filings, sometimes as an estimate made before CMS settled, so a filing can differ.
Per member per year: risk sharing ÷ Part D member-months × 12. Part D member-months include stand-alone drug plan (PDP) members.
CMS's reconciliation also settles reinsurance (catastrophic drug costs) and low-income cost sharing; those are pass-through subsidies, not a sign of profit or loss, so they're shown on contract pages only.
| 2024 | 2023 | 2022 | 3-year total | Per member per year2024 | Part D members2024 avg | |
|---|---|---|---|---|---|---|
| H6200 Essence Healthcare | $2.0M | $0 | — | $2.0M | $170 | 11,746 |
| H8229 Essence Healthcare | — | $8.4K | — | $8.4K | — | — |
| H4620 Essence Healthcare | $5.3K | −$6.4K | — | −$1.2K | $33 | 161 |
| H5372 Essence Healthcare | — | −$6.6K | — | −$6.6K | — | — |
| H3189 Essence Healthcare | −$12.1K | −$10.8K | — | −$22.9K | −$171 | 70 |
| H2986 Essence Healthcare | — | −$1.2M | −$1.1M | −$2.3M | — | — |
| H2610 Essence Healthcare | $3.2M | −$4.0M | −$5.3M | −$6.2M | $65 | 48,844 |
Red = CMS paid the plan. Sorted by the 3-year total. Parent totals add up each contract under its current parent; CMS also publishes its own parent rollup, which can differ where contracts changed hands.